24 completed, 5 terminated, 2 active not recruiting, 1 recruiting. 34 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Completed 24, Terminated 5, Active not recruiting 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments Remdesivir, Acalabrutinib, Interferon beta-1a - Covid19 | Phase 3 | Unknown | The University of The West Indies | 100 | 2021-06-01 | 2021-05-13 |
| Adaptive COVID-19 Treatment Trial 3 (ACTT-3) Interferon beta-1a, Placebo, Remdesivir - COVID-19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 969 | 2020-08-05 | 2022-03-14 |
| Trial of Treatments for COVID-19 in Hospitalized Adults Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A - Corona Virus Infection | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 1552 | 2020-03-22 | 2026-07-08 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis BIIB017 (peginterferon beta-1a), Interferon beta type 1a - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Active not recruiting | Biogen | 152 | 2019-10-18 | 2026-09-24 |
| Study of Evobrutinib in Participants With RMS Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 1 | 2019-09-10 | 2021-08-05 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2019-08-26 | 2021-08-05 |
| Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis BCD-054 180 mcg, Avonex®, BCD-054 240 mcg - Multiple Sclerosis, Relapsing-Remitting | Phase 2 / Phase 3 | Completed | Biocad | 399 | 2017-08-10 | 2021-09-08 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic) | Phase 3 | Recruiting | UMC Utrecht | 20000 | 2016-04-11 | 2026-11-04 |
| Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) Interferon beta-1a, Placebo - Respiratory Distress Syndrome, Adult | Phase 3 | Terminated | Faron Pharmaceuticals Ltd | 301 | 2015-12-23 | 2020-03-30 |
| Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis BCD-033 (interferon beta 1a), Rebif (interferon beta 1a), Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Biocad | 163 | 2015-02-12 | 2023-02-17 |
| Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) Ozanimod, Interferon beta-1a, Placebo to ozanimod - Multiple Sclerosis | Phase 3 | Completed | Celgene | 1346 | 2014-12-03 | 2020-11-25 |
| Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) dimethyl fumarate, Interferon β-1a - Relapsing-Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 156 | 2014-08-28 | 2026-05-19 |
| A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Laquinimod, Avonex® - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-01-01 | 2021-11-09 | |
| Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis Ozanimod, Ozanimod placebo, Interferon beta-1a - Relapsing Multiple Sclerosis | Phase 3 | Completed | Celgene | 1320 | 2013-12-03 | 2021-02-11 |
| Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis Interferon beta-1a, Fingolimod, Placebo capsule - Multiple Sclerosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 240 | 2013-07-26 | 2026-08-10 |
| A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 835 | 2011-09-20 | 2024-03-08 |
| A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 821 | 2011-08-31 | 2024-03-04 |
| National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis Interferon beta 1a, Mitoxantrone - Multiple Sclerosis | Phase 3 | Completed | Rennes University Hospital | 35 | 2010-12-06 | 2023-03-29 |
| Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a - Relapsing-Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 1841 | 2010-05-01 | 2016-07-11 |
| Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) Avonex - Multiple Sclerosis | Phase 3 | Completed | Biogen | 60 | 2010-04-01 | 2013-09-16 |
Showing 20 of 34. Sign in to see all of them.
Multiple Sclerosis (15) · Multiple Sclerosis, Relapsing-Remitting (13) · COVID-19 (4) · Pneumonia (2) · Autoimmune Diseases (1) · Community-Acquired Pneumonia (1) · Coronavirus Infections (1) · Hepatitis C (1) · Influenza, Human (1) · Lung Diseases (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Thinness (1)
Biogen (8) · Merck KGaA, Darmstadt, Germany (3) · Biocad (2) · Celgene (2) · EMD Serono (2) · EMD Serono Research & Development Institute, Inc. (2) · Genzyme, a Sanofi Company (2) · Hoffmann-La Roche (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Faron Pharmaceuticals Ltd (1) · Fred Lublin (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Rennes University Hospital (1)
United States (19) · Germany (17) · France (16) · Spain (16) · Canada (15) · Czechia (15) · Italy (15) · Poland (14) · Russia (14) · Belgium (12) · Serbia (12) · United Kingdom (12) · Croatia (11) · Bulgaria (10) · Australia (9)
Bettina M. Stubinski, MD (1) · Colin McArthur, Dr (1) · Derek Angus, Prof (1) · Florence Ader, MD (1) · Fred Lublin, MD (1) · Geoffrey Bellingan, MD (1) · Gordon Francis, M.D. (1) · James Sheffiled, MD (1)
PMID 34473343, PMID 36163349, PMID 37652990, PMID 27590291, PMID 28002679, PMID 30144037, PMID 31654272, PMID 31675266, PMID 31762387, PMID 32511687, PMID 32690791, PMID 32710396, PMID 33414927, PMID 33724637, PMID 34035833, PMID 34350582, PMID 34882037, PMID 34904871, PMID 35672926, PMID 36619856, PMID 36695483, PMID 36792367, PMID 37148240, PMID 37272540, PMID 37745914, PMID 39290861, PMID 39935588, PMID 39965438, PMID 40258203, PMID 40462564, PMID 40554392, PMID 40629721, PMID 42832215, PMID 17654600, PMID 21999176, PMID 22146409, PMID 23424159, PMID 24126064, PMID 24292999, PMID 24413638, PMID 24686106, PMID 25111080, PMID 26000222, PMID 26444729, PMID 27251051, PMID 28039317, PMID 28104250, PMID 28485186, PMID 28835401, PMID 28984179
2018 (3), 2014 (2), 2023 (2), 2004 (1), 2008 (1), 2009 (1), 2015 (1), U01NS045719 (1)